1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > PharmaPoint: Major Depressive Disorder - Australia Drug Forecast and Market Analysis to 2023

PharmaPoint: Major Depressive Disorder - Australia Drug Forecast and Market Analysis to 2023

  • May 2014
  • -
  • GlobalData
  • -
  • 154 pages

Summary

Table of Contents

PharmaPoint: Major Depressive Disorder - Australia Drug Forecast and Market Analysis to 2023

Summary

Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded and competitive market, with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly’s Cymbalta, and Otsuka/BMS’s Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takeda’s Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023.

Despite patent expiries for key products, Eli Lilly’s Cymbalta in 2013, Otsuka Pharmaceutical/BMS’s Abilify in 2016, and AstraZeneca’s Seroquel XR in 2017, the MDD market value in Australia is not anticipated to decline, as generic products are priced similarly to branded products and any loss of market value due to potential price discounts is expected to be offset by the increasing prevalent cases of MDD, the launch of Brintellix and the potential introduction of late-stage pipeline products during the forecast period.

Scope

- Overview of Major depressive disorder including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in Australia including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in Australia from 2013-2023.
- Analysis of the impact of key events as well the drivers and restraints affecting the Australia Major depressive disorder market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Major depressive disorder.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2013-2023 in Australia.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Antipsychotic Drugs Market By Drug Class (Haldo, Navane, Invega, Latuda, Seroquel, Risperdal, Zyprexa, Geodon, Abilify), By Application (Schizophrenia, Bipolar disorder, Dementia, Unipolar Depression) And Segment Forecasts, 2014 - 2025

Antipsychotic Drugs Market By Drug Class (Haldo, Navane, Invega, Latuda, Seroquel, Risperdal, Zyprexa, Geodon, Abilify), By Application (Schizophrenia, Bipolar disorder, Dementia, Unipolar Depression) And Segment Forecasts, 2014 - 2025

  • $ 4950
  • Industry report
  • February 2017
  • by Grand View Research

The global antipsychotic drugs market is expected to reach USD 14.4 billion by 2025, according to a new report by Grand View Research, Inc. The continuous development of better next-generation products ...

Global Antidepressants Market - Segmented by Antidepressant Therapies, Depressive Disorders, and Geography (2017 - 2022)

Global Antidepressants Market - Segmented by Antidepressant Therapies, Depressive Disorders, and Geography (2017 - 2022)

  • $ 4250
  • Industry report
  • January 2017
  • by Mordor Intelligence LLP

The global antidepressants market is estimated to grow to approximately USD 13.4 billion by 2020, at a CAGR of 1.8%. Depression affects an estimated 121 million people worldwide and the antidepressant ...

Global Lifestyle Drugs Market 2017-2021

Global Lifestyle Drugs Market 2017-2021

  • $ 3500
  • Industry report
  • February 2017
  • by Infiniti Research Limited

About Lifestyle Drugs Market Lifestyle disease is associated with the way an individual or group of people live. Some of the lifestyle diseases include depression, sexual dysfunction, anti-aging, baldness, ...


Download Unlimited Documents from Trusted Public Sources

Therapy Market in the US

  • April 2017
    44 pages
  • Therapy  

    Serotonin Speci...  

    Antidepressant  

  • United States  

View report >

Stroke Statistics in the US

  • April 2017
    4 pages
  • Stroke  

    Blood Disease  

  • United States  

View report >

Anti-Infective Market in the Netherlands and Germany

  • April 2017
    10 pages
  • Anti-Infective  

  • Netherlands  

    Germany  

    Europe  

View report >

Related Market Segments :

Depression

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.